iiBIG and the newly formed Global Biopharmaceutical Advisory Board have jointly planned an event that will focus on one of the most dynamic trends in the pharmaceutical, biotechnology, and medical device industries -- strategic outsourcing. Biopharma CEOs, VPs of Global Operations, and Department Heads will meet at the 4th Annual Global Clinical Trial Partnerships, March 1-2, 2010, in Princeton, New Jersey to discuss the latest strategies for optimizing global operations.
Key issues to be addressed include:
-- Ensuring competitive advantage through proven outsourcing strategies -- Understanding the latest global regulatory updates in pharma and medical device directives -- Sharing lessons learned to overcome multi-regional operational challenges -- Tackling the latest operational, regulatory and ethical issues in emerging markets: Pan-Asia, India, China, and Latin America -- Obtaining proven tools and techniques for successful patient recruitment
To address these issues, an outstanding speaking faculty of senior-level executives along with key operational leaders who handle global outsourcing and alliance management has been secured for this conference. Hear from representatives of large, medium, and small pharmaceutical as well as biotechnology and medical device companies as they share their insights on strategies for optimizing clinical operations and outsourcing. Some key faculty speakers include:
-- Luis Rios-Nogales, MD, PhD, MBA, Regional Medical Director ISMO Latin America Head, MCCD Clinical Research Region, AstraZeneca Latin America -- Christopher C. Gallen, MD, PhD, President and CEO, Neuromed Pharmaceuticals Inc. -- Ross D. Pettit, Vice President Operations, ARIAD Pharmaceuticals -- Christina DiArcangelo, Associate Director, Clinical Contracts and Outsourcing, Department Head, FibroGen, Inc. -- Raymond Panas, PhD, Director of International Clinical Development, Sucampo Pharmaceuticals -- Fidela Moreno, MD, Vice President Global Development, Clinical Site Management & Monitoring, Allergan For complete information about this event visit: www.iibig.com/P1001
Combination therapy shows promising results in treating stage 3 melanoma